Atara Biotherapeutics, Inc. (ATRA) SEC filings

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$7.93−0.30 (-3.65%)

Close on Nov 12, 2026Market cap $79.60MP/E –Yield –

SEC filings

40 of Atara Biotherapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 26, 2026	SEC EDGAR
Current report	8-K	Jun 9, 2026	Jun 12, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	May 1, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 24, 2026	Apr 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 20, 2026	Feb 23, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 30, 2025	Jan 2, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Oct 6, 2025	Oct 7, 2025	SEC EDGAR
Current report	8-K	Sep 2, 2025	Sep 4, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Jul 14, 2025	Jul 14, 2025	SEC EDGAR
Current report	8-K	Jun 10, 2025	Jun 11, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 16, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 15, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 15, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 12, 2025	SEC EDGAR
Current report	8-K	May 5, 2025	May 6, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 10, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Mar 31, 2025	Apr 4, 2025	SEC EDGAR
Current report	8-K	Mar 25, 2025	Mar 31, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 7, 2025	SEC EDGAR
Current report	8-K	Mar 7, 2025	Mar 7, 2025	SEC EDGAR
Current report	8-K	Mar 3, 2025	Mar 3, 2025	SEC EDGAR
Current report	8-K	Jan 27, 2025	Jan 27, 2025	SEC EDGAR
Current report	8-K	Jan 21, 2025	Jan 21, 2025	SEC EDGAR
Current report	8-K	Jan 16, 2025	Jan 16, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Atara Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jun 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ATRA.

Compare: ATRA vs TCRX · ATRA vs FATE · ATRA vs CRBU · ATRA vs DBVT · ATRA vs MOLN

Revenue growth-97.4% · median -32.5%

Operating margin-343.6% · median -2503.4%

Net margin-368.6% · median -2419.4%

Company	Revenue	Growth
CRBU	$9.44M	+1.6%
TCRX	$5.19M	-38.4%
FATE	$4.75M	-33.4%
ATRA	$3.97M	-97.4%
DBVT	$3.84M	-31.6%
MOLN	–	–

Company

Next earnings (est.): Mar 15, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 14
Held by institutions: 44.5%
Auditor: DELOITTE & TOUCHE LLP
SEC CIK: 1604464

Advertisement
300 × 250

See a number that looks wrong?